written on 10.03.2014

Long-acting hemophilia meds portend a pricing fight with older drugs


New, long-acting clotting factors are on their way, with Biogen Idec's hemophilia B drug Alprolix first in line. The new treatments promise to prevent bleeding for up to two weeks, and that means today's injections will have to find a way to compete.